Two New Dosage Strengths Of Stalevo(R) Approved In The U.S. Provide Greater Dosing Flexibility For People With Parkinson’s Disease
Oct 29th 2008Drug InformationParkinson's Disease
Novartis Pharmaceuticals Corporation today announced the launch of two new FDA-approved dosage strengths of Stalevo(R) (carbidopa, levodopa and entacapone), which is indicated for certain people with Parkinson’s disease who experience end-of-dose “wearing off”. The approval of Stalevo 75 and 125 tablets (18.75 mg carbidopa, 75 mg levodopa, 200 mg entacapone and 31.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
